Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.
The cancer challenge is affecting more and more people worldwide, with 21 million cases expected by 2030.
Trump calls pharma leaders to White House to discuss cutting taxes, regulations – and drug prices
Roche’s PD-L1 drug has generated impressive data in second line lung cancer
Merck unveils impressive data on Keytruda, trumping BMS’ Opdivo
Europe’s biggest cancer conference ESMO is underway
Merck steals a march on rival BMS.
Sanofi has competition in its bid to acquire cancer specialist
Analysts expect Opdivo to recover via combination trials